News & Updates

Self-monitoring improves postpartum BP control in women with hypertensive pregnancy

27 Nov 2023 by

Empowering mums to self-monitor their blood pressure (BP) with a physician-guided titration of antihypertensive medications helps lower postpartum BP level after a pregnancy complicated by hypertension, as shown in the POP-HT trial.

Self-monitoring improves postpartum BP control in women with hypertensive pregnancy

27 Nov 2023

Battle of stents: Is skinnier better?

25 Nov 2023 by

An ultrathin stent performed just as well as the conventional thin-strut stent in patients at high risk of bleeding in the first head-to-head COMPARE 60/80 trial, providing a new and effective drug-eluting stent (DES) option.

Battle of stents: Is skinnier better?

25 Nov 2023

Vaginal micronized progesterone lowers risk of hypertensive disorders of pregnancy

23 Nov 2023

Initiation of vaginal micronized progesterone during the first trimester appears to reduce the risk of hypertensive disorders of pregnancy (HDP) and pre-eclampsia, according to a study.

Vaginal micronized progesterone lowers risk of hypertensive disorders of pregnancy

23 Nov 2023

Intensive BP-lowering reduces dementia risk in patients with hypertension

23 Nov 2023 by

Among Chinese patients with hypertension, a 48-month intensive blood pressure (BP) intervention programme significantly reduces the risk of developing dementia than usual care, according to a study presented at AHA 2023.

Intensive BP-lowering reduces dementia risk in patients with hypertension

23 Nov 2023

More evidence support ticagrelor monotherapy after <1-month DAPT in ACS

22 Nov 2023 by

Dropping aspirin after <1 month of dual antiplatelet therapy (DAPT) with ticagrelor is superior to continuing both drugs through 12 months in patients with acute coronary syndrome (ACS) implanted with drug-eluting stents in the T-PASS trial.

More evidence support ticagrelor monotherapy after <1-month DAPT in ACS

22 Nov 2023

Alpha blockers tied to less favourable cardiovascular profile than 5-ARIs in BPH

21 Nov 2023

In the treatment of men with benign prostatic hyperplasia (BPH), alpha blockers appear to be associated with worse cardiovascular outcomes compared with 5-alpha reductase inhibitors (5-ARIs), as shown in a study.

Alpha blockers tied to less favourable cardiovascular profile than 5-ARIs in BPH

21 Nov 2023

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023 by

Treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) among overweight/obese patients with pre-existing cardiovascular (CV) disease but without type 2 diabetes (T2D), according to the SELECT trial presented at AHA 2023.

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023

Remdesivir, favipiravir may not be heart-friendly

20 Nov 2023 by

Remdesivir and favipiravir does not appear to be heart-friendly in patients with COVID-19, according to a study presented at APSR 2023.

Remdesivir, favipiravir may not be heart-friendly

20 Nov 2023

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023 by

Use of antihypertensive medications does not appear to reduce the risk of all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF), reports a study presented at AHA 2023. However, treatment with antihypertensives can lower the risk of adverse cardiovascular (CV) outcomes regardless of the patient’s hypertension status.

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Self-monitoring improves postpartum BP control in women with hypertensive pregnancy

Self-monitoring improves postpartum BP control in women with hypertensive pregnancy

Battle of stents: Is skinnier better?

Battle of stents: Is skinnier better?

Vaginal micronized progesterone lowers risk of hypertensive disorders of pregnancy

Vaginal micronized progesterone lowers risk of hypertensive disorders of pregnancy

Intensive BP-lowering reduces dementia risk in patients with hypertension

Intensive BP-lowering reduces dementia risk in patients with hypertension

More evidence support ticagrelor monotherapy after <1-month DAPT in ACS

More evidence support ticagrelor monotherapy after <1-month DAPT in ACS

Alpha blockers tied to less favourable cardiovascular profile than 5-ARIs in BPH

Alpha blockers tied to less favourable cardiovascular profile than 5-ARIs in BPH

Semaglutide reduces CV risk in overweight/obese patients without T2D

Semaglutide reduces CV risk in overweight/obese patients without T2D

Remdesivir, favipiravir may not be heart-friendly

Remdesivir, favipiravir may not be heart-friendly

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Dapagliflozin offers cardioprotection in HF patients with T2D

Dapagliflozin offers cardioprotection in HF patients with T2D